# idiopathic pulmonary fibrosis (IPF) - deepseek-v4-flash

- Benchmark system: raw
- Repeat: 2
- Task type: PROGNOSIS
- Tissue / sample source: lung tissue
- Comparison or endpoint: all-cause mortality
- Answer input cohort: Discovery/Core only
- Selected items: 100
- Input fields: gene name, effect size (log2FC/HR), P value, FDR
- E2seq Agent RAG: disabled
- Conversation memory: disabled
- Thinking mode: disabled
- Held-out validation data in prompt/RAG: no
- Model API: DeepSeek / deepseek-v4-flash
- Message SHA-256: d9fe74e971569d03f1ace047ce334e08d788b93d2057913b4d42b34da6d57d2f
- Response HTTP status: 200
- Prompt tokens: 3867
- Completion tokens: 23904
- Reasoning tokens: 
- Total tokens: 27771
- API requests reported: 
- Elapsed seconds: 250.834
- Final benchmark system: raw; file rank 2/5; original repeat 2; model vendor: DeepSeek

---
# Prognostic transcriptomic interpretation in IPF lung tissue

This is a prognostic screen, not a differential expression screen. The reported effect size is the hazard ratio (HR), so HR > 1 means that higher expression of that gene in lung tissue is associated with increased all-cause mortality; HR < 1 is protective. No disease-state log2 fold-change data were supplied.

Before biological interpretation, several extreme rows should be set aside. Genes with HR values near \(10^{-22}\) or \(>10^{21}\) — for example MIR221, IHH, HCN4, FAM75A2, OR2M2, DYDC2, DKFZP434L187, XLOC_003303, and the two CONTROL probes — are not biologically plausible as prognostic effects. They almost certainly reflect near-zero expression, very sparse detection, or numerical instability in the Cox model. They are therefore not used in the biological interpretation below.

---

## 1. Overall biological interpretation

The statistically reliable prognostic signal in IPF lung tissue is dominated by genes associated with:

- Innate immune / neutrophilic inflammation and alarmin signaling.
- Aberrant epithelial differentiation, including mucin production, alveolar type II hyperplasia, and squamous metaplasia.
- Extracellular matrix remodeling and matricellular / profibrotic activity.
- Growth factor / receptor tyrosine kinase signaling.
- A weaker but consistent oxidative stress / metabolic adaptation signal.

Together, these themes point to a maladaptive tissue-repair response: persistent epithelial injury, recruitment and activation of innate immune cells, and progressive fibrotic remodeling. The mortality-associated transcriptome is not a single pathway but a coordinated set of epithelial, immune, and mesenchymal programs that likely reflect the severity and activity of the fibrotic process.

The only credible protective gene in this list is LOC100128226, an uncharacterized long non-coding RNA with HR ≈ 0.007 and very strong statistical evidence. Because its function is unknown and the HR is extreme, it should be treated as a candidate biomarker / biological curiosity rather than as an interpretable protective mechanism.

---

## 2. Core biological programs

### Program 1: Innate immune / neutrophil / alarmin inflammation

**Direction:** Risk-associated (HR > 1).

**Major supporting genes:** S100A12, CXCL1, CXCR1, CD177, SELL, CEACAM6, CEACAM7, MMP25, CYP4F3, ANKRD22, STEAP4.

**Standardized pathway:** Reactome “Neutrophil Degranulation”; GO:0043312 “Neutrophil degranulation”; Hallmark “Inflammatory Response.”

**Explanation:** Multiple genes in this group are neutrophil-expressed or neutrophil-recruiting. S100A12 is an alarmin; CXCL1 and CXCR1 are a chemokine–receptor pair; CD177 and SELL are leukocyte/neutrophil surface markers; MMP25 is a neutrophil protease; CYP4F3 is involved in leukotriene metabolism. The co-occurrence of these genes strongly suggests that active neutrophilic inflammation, not just end-stage fibrosis, is associated with increased mortality in IPF.

**Strength of evidence:** High, because the program is supported by many independent genes and a coherent biological pathway.

**Major limitation:** Bulk lung tissue contains variable numbers of neutrophils. The signal may partly reflect neutrophil abundance rather than increased per-cell expression.

---

### Program 2: Aberrant epithelial differentiation / mucin metaplasia / alveolar type II hyperplasia

**Direction:** Risk-associated.

**Major supporting genes:** MUC1, MUC21, GALNT14, CEACAM6, CEACAM7, AGR3, KRT17, KRT23, SPRR1A, SFTPB, SFTA2, SLC34A2, MAL2, PRSS8, IRX2.

**Standardized pathway:** GO:0030855 “Epithelial cell differentiation”; KEGG hsa00512 “Mucin type O-glycan biosynthesis” for the GALNT14 / mucin component.

**Explanation:** MUC1 and MUC21 are membrane mucins; GALNT14 controls an early step in mucin-type O-glycosylation. KRT17, KRT23, and SPRR1A are markers of abnormal squamous / keratinizing epithelial differentiation. SFTPB, SFTA2, and SLC34A2 are alveolar type II cell–associated genes, consistent with type II pneumocyte hyperplasia. Together, these genes indicate a major disruption of alveolar epithelial homeostasis: mucous metaplasia, basal / squamous differentiation, and surfactant-producing epithelial proliferation.

**Strength of evidence:** High, due to the number and coherence of epithelial markers.

**Major limitation:** Epithelial composition changes dramatically in fibrotic lung. The signal could largely reflect the extent of honeycombing and metaplastic epithelium rather than a specific molecular driver.

---

### Program 3: Extracellular matrix remodeling and matricellular / profibrotic response

**Direction:** Risk-associated.

**Major supporting genes:** HTRA1, EFEMP1, SPP1, FBLIM1, CHST15, HS3ST1, FHL2, BMP6, SOD3, F5.

**Standardized pathway:** Reactome “Extracellular matrix organization”; GO:0030198 “Extracellular matrix organization.”

**Explanation:** HTRA1 is an ECM-degrading serine protease; EFEMP1 / fibulin-3 is a matricellular ECM protein; SPP1 / osteopontin is a profibrotic matricellular cytokine; CHST15 and HS3ST1 modify sulfated glycosaminoglycans in the ECM; FBLIM1 links cell–matrix adhesions to the actin cytoskeleton. The simultaneous enrichment of ECM remodeling, matricellular signaling, and cell–matrix adhesion genes implies active, ongoing fibrotic remodeling rather than merely the presence of scar tissue.

**Strength of evidence:** High, with multiple genes in the ECM / adhesion / matricellular space.

**Major limitation:** These genes may arise from multiple cell types — fibroblasts, myofibroblasts, macrophages, and epithelium — so the causal cell source cannot be identified from bulk tissue alone.

---

### Program 4: Growth factor / receptor tyrosine kinase signaling

**Direction:** Risk-associated.

**Major supporting genes:** MET, HGF, NRG1, MERTK, SPRY2, RGL1, RAB3IL1, MARCKS.

**Standardized pathway:** Reactome “Signaling by Receptor Tyrosine Kinases.”

**Explanation:** This group contains a ligand–receptor pair (HGF and MET), a growth factor ligand (NRG1), a receptor tyrosine kinase (MERTK), and a downstream feedback regulator (SPRY2). SPRY2 is particularly informative because it is a transcriptional feedback inhibitor of RTK signaling; its upregulation together with MET, HGF, NRG1, and MERTK suggests sustained engagement of RTK growth-factor programs. This may reflect epithelial repair signaling, macrophage activation, or mesenchymal proliferation.

**Strength of evidence:** Moderate to high, but somewhat less lineage-specific than Programs 1–3.

**Major limitation:** Some of these genes, especially HGF, have been described as anti-fibrotic or protective in experimental systems. The risk association in this dataset may represent a compensatory repair response or disease-severity correlation rather than a direct causal driver.

---

### Program 5: Oxidative stress / metabolic adaptation (exploratory)

**Direction:** Risk-associated.

**Major supporting genes:** SLC7A11, SLC6A8, SLC39A8, STEAP4, ACOX2, ALDH1A3, SOD3.

**Standardized pathway:** GO:0006979 “Response to oxidative stress”; Hallmark “Reactive Oxygen Species Pathway.”

**Explanation:** SLC7A11 encodes the cystine/glutamate antiporter central to glutathione synthesis and ferroptosis defense; STEAP4 is a metalloreductase; SOD3 is an extracellular antioxidant enzyme; ACOX2 is a peroxisomal fatty-acid oxidation enzyme; SLC39A8 is a zinc transporter with inflammatory roles. These genes suggest metabolic and oxidative stress adaptation in the injured lung.

**Strength of evidence:** Weaker than Programs 1–4. The genes are functionally diverse, and some are broad housekeeping-type transporters. This program should be treated as exploratory.

**Major limitation:** The pathway is broad and may partly reflect differences in epithelial or inflammatory cell composition rather than a specific metabolic state.

---

## 3. Key genes and interaction modules

The following modules are chosen because they are statistically strong, biologically coherent, and likely to be useful for validation.

### 1. Profibrotic macrophage module: MERTK / SPP1 / STAB1

- MERTK: HR ≈ 3.70, FDR ≈ 1.0 × 10⁻⁵  
- SPP1: HR ≈ 3.40, FDR ≈ 4.0 × 10⁻⁵  
- STAB1: HR ≈ 3.29, FDR ≈ 3.1 × 10⁻⁵  

**Potential role:** MERTK is a TAM receptor tyrosine kinase involved in efferocytosis; SPP1 / osteopontin is a matricellular cytokine; STAB1 / stabilin-1 marks alternatively activated / scavenging macrophages. Together they point to a profibrotic macrophage population.

**Gene-gene relationship:** These genes likely co-occur in the same macrophage activation program, but the input table does not demonstrate co-expression. This should be considered **pathway co-membership / shared cell-type association**, not direct physical interaction.

---

### 2. ECM protease / matricellular module: HTRA1 / EFEMP1 / CHST15 / HS3ST1

- HTRA1: HR ≈ 4.30, FDR ≈ 2.6 × 10⁻⁶  
- EFEMP1: HR ≈ 2.33, FDR ≈ 2.7 × 10⁻⁵  
- CHST15: HR ≈ 2.99, FDR ≈ 2.1 × 10⁻⁵  
- HS3ST1: HR ≈ 3.24, FDR ≈ 3.5 × 10⁻⁵  

**Potential role:** Active ECM turnover, proteoglycan modification, and matricellular signaling associated with progressive fibrosis.

**Gene-gene relationship:** **Pathway co-membership** in extracellular matrix organization. No direct physical interaction is supported by the input data.

---

### 3. HGF / MET ligand–receptor module

- HGF: HR ≈ 2.93, FDR ≈ 1.1 × 10⁻⁵  
- MET: HR ≈ 2.53, FDR ≈ 1.5 × 10⁻⁵  

**Potential role:** HGF is the canonical MET ligand. The fact that both ligand and receptor are risk-associated suggests activation of this axis, or a compensatory epithelial / mesenchymal repair response.

**Gene-gene relationship:** This is a known **direct ligand–receptor physical interaction** from external biochemical literature. However, the current dataset only shows parallel prognostic association, not direct molecular binding.

**Important conflict:** HGF is often considered anti-fibrotic in experimental IPF models. The risk association here may reflect disease severity, cell-type-specific effects, or a failed repair response. This should not be interpreted as evidence that HGF/MET activation is causally harmful.

---

### 4. NRG1 growth-factor signaling

- NRG1: HR ≈ 2.76, FDR ≈ 6.9 × 10⁻⁶

**Potential role:** NRG1 is a ligand for ERBB3 / ERBB4 receptors and can drive epithelial proliferation and repair. It may act in parallel with the HGF/MET program.

**Gene-gene relationship:** NRG1–ERBB is a known **direct ligand–receptor interaction** in the literature, but ERBB genes are not present in this dataset, so the pathway link here is inferred rather than directly evidenced.

---

### 5. Mucin / O-glycosylation module: MUC1 / MUC21 / GALNT14

- MUC1: HR ≈ 2.32, FDR ≈ 1.1 × 10⁻⁵  
- MUC21: HR ≈ 2.10, FDR ≈ 2.8 × 10⁻⁵  
- GALNT14: HR ≈ 3.11, FDR ≈ 5.5 × 10⁻⁶  

**Potential role:** Mucin hypersecretion and aberrant epithelial differentiation. MUC1 is already a candidate serum biomarker in IPF.

**Gene-gene relationship:** GALNT14 is an enzyme involved in mucin-type O-glycosylation; MUC1 and MUC21 are mucin substrates. This is best described as a **regulatory / enzyme–substrate relationship** at the pathway level, not necessarily a direct physical interaction with these specific mucins in this dataset.

---

### 6. Neutrophil chemokine / alarmin module: CXCL1 / CXCR1 / CD177 / S100A12 / CYP4F3

- CXCL1: HR ≈ 2.99, FDR ≈ 3.7 × 10⁻⁵  
- CXCR1: HR ≈ 3.28, FDR ≈ 1.6 × 10⁻⁵  
- CD177: HR ≈ 2.72, FDR ≈ 3.9 × 10⁻⁵  
- S100A12: HR ≈ 2.53, FDR ≈ 5.5 × 10⁻⁶  
- CYP4F3: HR ≈ 3.78, FDR ≈ 9.5 × 10⁻⁸  

**Potential role:** Neutrophil recruitment, chemokine signaling, and alarmin release. This module is the strongest single evidence for active innate immune inflammation as a mortality-associated process.

**Gene-gene relationship:** CXCL1–CXCR1 is a known **direct ligand–receptor interaction**. S100A12 can signal through RAGE, also a **direct ligand–receptor interaction** in the external literature. Other genes are best viewed as **pathway co-members** in the neutrophil program.

---

### 7. Epithelial metaplasia / keratinization module: KRT17 / KRT23 / SPRR1A / SFTPB / SFTA2

- KRT17: HR ≈ 2.19, FDR ≈ 3.3 × 10⁻⁵  
- KRT23: HR ≈ 2.59, FDR ≈ 2.6 × 10⁻⁵  
- SPRR1A: HR ≈ 2.28, FDR ≈ 2.7 × 10⁻⁵  
- SFTPB: HR ≈ 2.66, FDR ≈ 3.4 × 10⁻⁵  
- SFTA2: HR ≈ 2.25, FDR ≈ 2.9 × 10⁻⁵  

**Potential role:** Abnormal airway / alveolar epithelial differentiation, including squamous metaplasia and surfactant-producing alveolar type II hyperplasia. These are classic features of IPF honeycomb lung.

**Gene-gene relationship:** **Pathway co-membership** in keratinization / epithelial differentiation. No direct physical interaction should be claimed from this dataset.

---

### 8. Oxidative stress / ferroptosis defense module: SLC7A11 / STEAP4 / SOD3

- SLC7A11: HR ≈ 3.52, FDR ≈ 1.1 × 10⁻⁵  
- STEAP4: HR ≈ 3.03, FDR ≈ 1.9 × 10⁻⁵  
- SOD3: HR ≈ 2.37, FDR ≈ 2.7 × 10⁻⁵  

**Potential role:** Metabolic adaptation to oxidative injury. SLC7A11 is particularly interesting because it links glutathione metabolism and ferroptosis resistance.

**Gene-gene relationship:** **Pathway co-membership** in oxidative stress response. No direct interaction is supported by the input data.

---

### 9. LOC100128226 — protective uncharacterized lncRNA

- HR ≈ 0.007, FDR ≈ 4.8 × 10⁻³⁵

**Potential role:** Unknown. This is a statistically strong protective association, but the HR is extremely low and the gene is poorly annotated. It could be a real biomarker, a low-expression artifact, or a probe artifact.

**Gene-gene relationship:** None identified.

**Conclusion:** **Insufficient evidence** for mechanistic interpretation at present.

---

## 4. Validation priorities

### 1. Cell-composition confounding check

**Classification:** Confounding / composition check.

**Why it deserves priority:** Many of the strongest risk genes are lineage markers for neutrophils, macrophages, or epithelial cells. In bulk IPF lung tissue, their HRs may reflect changes in cell abundance rather than cell-intrinsic gene expression changes.

**Evidence from current dataset:** S100A12, CD177, CXCR1, and CYP4F3 suggest neutrophil abundance; MERTK, SPP1, and STAB1 suggest macrophage abundance; SFTPB, SFTA2, MUC1, and KRT17 suggest epithelial remodeling.

**External evidence:** IPF lungs are known to contain altered proportions of neutrophils, macrophages, basal-like epithelial cells, and fibroblasts.

**Next step:** Perform single-cell / single-nucleus RNA-seq, spatial transcriptomics, or computational deconvolution of bulk tissue to determine whether the mortality-associated genes are truly upregulated in specific cell populations or simply reflect increased cellularity.

**Current status:** **Established evidence** that tissue composition is a major confounder; **not established** that the expression changes are cell-intrinsic.

---

### 2. Functional testing of the profibrotic macrophage module

**Classification:** Mechanistic hypothesis.

**Why it deserves priority:** MERTK, SPP1, and STAB1 form a coherent risk-associated macrophage module. This is testable with existing genetic tools.

**Evidence from current dataset:** All three genes have HRs between 3.29 and 3.70 with FDR < 5 × 10⁻⁵.

**External evidence:** SPP1⁺ macrophages and MERTK-dependent efferocytosis have been linked to fibrosis in experimental models and IPF single-cell studies.

**Next step:** Conditional deletion of Mertk or Spp1 in macrophages in preclinical IPF models; assess fibrosis, inflammatory cell accumulation, and survival.

**Current status:** **Supported hypothesis**, not established causal mechanism.

---

### 3. Biomarker validation of MUC1 / SFTPB / SPP1

**Classification:** Biomarker.

**Why it deserves priority:** These genes encode secreted or membrane proteins that may be detectable in plasma or serum, and MUC1 and SFTPB already have clinical biomarker precedent in IPF.

**Evidence from current dataset:** MUC1 HR ≈ 2.32, SFTPB HR ≈ 2.66, SPP1 HR ≈ 3.40, all with FDR < 4 × 10⁻⁵.

**External evidence:** Serum SFTPB and MUC1 / KL-6 are associated with IPF prognosis; SPP1 protein is elevated in IPF lungs.

**Next step:** Test protein levels in plasma / serum and tissue in an independent IPF cohort, adjusting for age, sex, baseline lung function, and disease severity.

**Current status:** **Supported hypothesis** for tissue transcript expression; serum biomarker value is still **exploratory**.

---

### 4. Resolving the HGF / MET and NRG1 signaling direction

**Classification:** Interaction / network hypothesis.

**Why it deserves priority:** HGF and MET are both risk-associated, but HGF has often been considered anti-fibrotic. This conflict is important for interpreting whether RTK signaling is a driver or a compensatory response.

**Evidence from current dataset:** HGF HR ≈ 2.93, MET HR ≈ 2.53, NRG1 HR ≈ 2.76, SPRY2 HR ≈ 3.26.

**External evidence:** Experimental HGF administration is protective in some lung fibrosis models, which conflicts with the risk association seen here.

**Next step:** Use phospho-RTK assays, epithelial–fibroblast co-culture, and receptor inhibition or ligand stimulation in IPF organoids or animal models to determine whether MET or ERBB pathway activation is protective or harmful in this context.

**Current status:** **Exploratory hypothesis**; the direction of causality remains unresolved.

---

### 5. SLC7A11 / oxidative stress as a therapeutic hypothesis

**Classification:** Therapeutic target.

**Why it deserves priority:** SLC7A11 is a central regulator of glutathione synthesis and ferroptosis, and it is a risk-associated gene in this dataset.

**Evidence from current dataset:** SLC7A11 HR ≈ 3.52 with strong statistical significance; it is supported by other oxidative stress / metabolic genes such as STEAP4 and SOD3.

**External evidence:** Ferroptosis and oxidative stress have been implicated in lung injury and fibrosis. However, the existence of ferroptosis-modulating drugs is not evidence that they are effective or appropriate in IPF.

**Next step:** Cell-type-specific genetic deletion or pharmacological modulation of SLC7A11 in preclinical IPF models, with careful assessment of epithelial versus macrophage contributions.

**Current status:** **Exploratory hypothesis**, not a validated therapeutic target.

---

## 5. Evidence grounding

The interpretation above relies on several evidence categories:

- **Direct evidence from the input dataset:** HRs, P values, and FDRs. This is the only statistical evidence used.
- **Pathway / ontology evidence:** GO and Reactome annotations, which help organize the genes but are not statistically independent of the gene list.
- **Protein interaction / regulatory evidence:** For HGF–MET, CXCL1–CXCR1, and NRG1–ERBB, ligand–receptor interactions are known from external biochemistry. These are separate from the prognostic association but do not prove pathway activity in IPF.
- **Disease-association evidence:** Many genes, including SPP1, MERTK, MUC1, and SFTPB, have previously been associated with IPF. This supports biological plausibility.
- **Expression / tissue-specific evidence:** The cell-type patterns of these genes — neutrophils, macrophages, alveolar epithelium — help explain the composition-confounder risk.
- **Genetic / clinical evidence:** None was supplied.
- **Drug / therapeutic evidence:** None. The availability of drugs targeting any of these genes was not used as evidence of efficacy.

An important independence note: the pathway annotations and the disease-association literature are partly overlapping with the input data, because both may derive from bulk transcriptomic studies of IPF tissue. Therefore, concordance between them is supportive but not fully independent confirmation.

The main conflict in the literature is with HGF. Experimental literature often associates HGF with protective or anti-fibrotic effects, while this dataset associates HGF expression with increased mortality. This does not mean either is wrong; it likely reflects the difference between a bulk-tissue prognostic marker and a causal biological perturbation.

---

## 6. Limitations and alternative explanations

### 1. Bulk tissue and cell-composition differences

The strongest limitation is tissue heterogeneity. IPF lung tissue contains variable amounts of alveolar epithelium, metaplastic epithelium, fibroblasts, myofibroblasts, macrophages, neutrophils, lymphocytes, and vasculature. Many risk-associated genes may simply mark increased cell abundance. This can be investigated by single-cell / spatial transcriptomics, deconvolution, and flow cytometry.

### 2. Unstable extreme HRs and probe artifacts

Several rows have HR values near \(10^{-22}\) or \(>10^{21}\). These are not plausible and likely represent near-zero expression, sparse events, or numerical artifacts. The only way to resolve them is to check raw expression distributions and remove low-variance / low-expression probes before any pathway analysis. Including these rows in functional interpretations would be misleading.

### 3. Disease severity, treatment exposure, and clinical covariates

The endpoint is all-cause mortality. The input does not include age, sex, baseline lung function, antifibrotic or immunosuppressive treatment, smoking status, or disease stage. Therefore, the HRs are unadjusted for major prognostic covariates. Some genes may be associated with mortality simply because they mark more severe disease at sampling time.

### 4. Broad or nonspecific pathway enrichment

Some programs, particularly oxidative stress and epithelial differentiation, are broad and include genes with diverse functions. Without a formal pathway-enrichment analysis using ranked gene statistics, it is difficult to know whether the apparent enrichment is stronger than expected by chance. The gene-level FDRs are strong, but the pathway-level conclusions are more subjective.

### 5. Association-versus-causation ambiguity

All conclusions from this dataset are prognostic associations. They do not establish that a gene causes mortality or that suppressing it would improve outcomes. This is especially important for HGF/MET, MERTK, and SLC7A11, where the same gene may have protective or harmful roles depending on cell type and disease stage.

---

## Summary

The most robust biological interpretation of this prognostic IPF transcriptome is that mortality risk is associated with a combination of active innate immune / neutrophilic inflammation, aberrant epithelial differentiation, ECM remodeling, and growth-factor signaling. The strongest single-cell type hypothesis is a profibrotic macrophage / myeloid program involving MERTK, SPP1, and STAB1. The most important technical caveat is that bulk tissue composition may explain a substantial part of the signal. Future work should prioritize cell-resolved expression analysis and functional perturbation experiments before any therapeutic conclusions are drawn.
